Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. DUODOPA (carbidopa/ lévodopa)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

DUODOPA (carbidopa/ lévodopa)

Medicine - Posted on Nov 18 2019
Active substance (DCI)
  • carbidopa
  • lévodopa
history (4)
  • 10/23/19

    DUODOPA (carbidopa/ lévodopa)

    L’essentiel Avis favorable au maintien du remboursement dans le traitement de la maladie de Parkinson à un stade avancé avec...
    icône flèche
  • 7/24/13

    DUODOPA (carbidopa/ lévodopa)

    DUODOPA (carbidopa/ lévodopa)
    icône flèche
  • 10/24/07

    DUODOPA (carbidopa/ lévodopa)

    DUODOPA (carbidopa/ lévodopa)
    CAV :
    54321
    icône flèche
  • 4/26/06

    DUODOPA (carbidopa/ lévodopa)

    DUODOPA (carbidopa/ lévodopa)
    CAV :
    54321
    icône flèche
Technical information
ATC code
  • N04BA02
Manufacturer
ABBVIE
Presentation

DUODOPA 20 mg/ml + 5 mg/ml, gel intestinal
B/ 7 sachets PVC de 100 ml contenant 2000 mg de lévodopa et 500 mg de carbidopa - Code CIP : 34009 365 110 0 2

All our publications
    Central nervous system diseases Drug therapy Geriatrics Neurodegenerative diseases

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
Q7Pf6UQ3bvn6Vreh